Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives:

Global & Regional Health Technology Assessment

CarlaRognoni¹ 

关键词: Rituximab;    biosimilar;    budget impact analysis;    economic evaluation;   

DOI  :  10.1177/2284240318784289

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

Introduction:This article aims at investigating the 5-year budget impact of rituximab biosimilars in Italy.Methods:A budget impact analysis model was developed in accordance with the International Society For Pharmacoeconomics and Outcomes Research recommendations. Drug acquisition and drug administration costs were considered since the risk/benefit profile of biosimilars and the originator was assumed to be overlapping. The perspectives of hospitals and payers were used. Input data were retrieved from the literature and validated/integrated by an expert panel of seven clinicians from various Italian regions. A dynamic incidence-based approach was used.Results:From the hospital perspective, adopting a rituximab biosimilar would produce savings of €79.2 and €153.6 million over 3 and 5 years, respectively. The results are very similar if the payer perspective is considered, with a cumulated savings of about €153.4 million in 5 years. Lymphoma and chronic lymphocytic leukaemia would account for the most sign...

【 授权许可】

CC BY